← Back to Search

NMDA Receptor Antagonist

Ketamine for Cardiac Arrest (KetCat Trial)

N/A
Recruiting
Research Sponsored by Fraser Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 months.
Awards & highlights

KetCat Trial Summary

This trial is testing whether ketamine can help people who have had a cardiac arrest and might improve their neurological function.

Eligible Conditions
  • Neurologic Symptoms
  • Cardiac Arrest
  • Ketamine

KetCat Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 6 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility Data

Side effects data

From 2020 Phase 4 trial • 75 Patients • NCT03156504
1%
Lightheadedness with low blood pressure
1%
Pump Malfunction
1%
PTSD
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ketamine

KetCat Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ketamine ArmExperimental Treatment1 Intervention
Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
Group II: Control ArmActive Control1 Intervention
Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine Hydrochloride
2018
Completed Phase 4
~910

Find a Location

Who is running the clinical trial?

Fraser HealthLead Sponsor
45 Previous Clinical Trials
707,466 Total Patients Enrolled

Media Library

Ketamine Hydrochloride (NMDA Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT04360070 — N/A
Neurologic Symptoms Research Study Groups: Ketamine Arm, Control Arm
Neurologic Symptoms Clinical Trial 2023: Ketamine Hydrochloride Highlights & Side Effects. Trial Name: NCT04360070 — N/A
Ketamine Hydrochloride (NMDA Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04360070 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
The Application of Ketamine for Sedation in Patients With Cardiac Arrest - - KetCat (KETamine in Cardiac ArresT) Study
George Medvedev 2022. "The Application of Ketamine for Sedation in Patients With Cardiac Arrest - - KetCat (KETamine in Cardiac ArresT) Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04360070.
All > Cardiac Arrest
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top